生物技术通讯
生物技術通訊
생물기술통신
LETTERS IN BIOTECHNOLOGY
2013年
2期
200-204
,共5页
任皎%姜云水%高孟%赵莉%庄昉成%谭文杰%阮力%毛子安%田厚文
任皎%薑雲水%高孟%趙莉%莊昉成%譚文傑%阮力%毛子安%田厚文
임교%강운수%고맹%조리%장방성%담문걸%원력%모자안%전후문
人乳头瘤病毒%宫颈癌%免疫治疗%联合免疫
人乳頭瘤病毒%宮頸癌%免疫治療%聯閤免疫
인유두류병독%궁경암%면역치료%연합면역
human papillomavirus%cervical cancer%immuno-therapy%prime-boost immunity
目的:探索联合免疫策略对人乳头瘤病毒16型(HPV16)治疗疫苗 L2E7E6和 rAdE7E6的免疫效果的影响.方法:用 L2E7E6融合蛋白和重组腺病毒 rAd5E7E6以不同的联合免疫程序分别免疫 C57BL/6小鼠,通过检测其诱发的体液免疫和细胞免疫反应,以及观察其在 HPV16小鼠治疗模型中的抑瘤效果,比较分析联合免疫对小鼠免疫反应及治疗肿瘤效果的影响.结果:异性联合免疫组均可检测到较高水平的体液免疫,该2组针对 E6、E7特异性的 T 细胞免疫反应与同性联合免疫2组相比明显提高,并在小鼠肿瘤治疗模型中能抑制肿瘤生长.结论:异性联合免疫策略可明显提高 HPV16 L2E7E6及 rAd5E7E6疫苗的 T 细胞免疫反应,且有效治疗 HPV16相关肿瘤,为 HPV16 L2E7E6及 rAd5E7E6疫苗的应用提供了实验基础.
目的:探索聯閤免疫策略對人乳頭瘤病毒16型(HPV16)治療疫苗 L2E7E6和 rAdE7E6的免疫效果的影響.方法:用 L2E7E6融閤蛋白和重組腺病毒 rAd5E7E6以不同的聯閤免疫程序分彆免疫 C57BL/6小鼠,通過檢測其誘髮的體液免疫和細胞免疫反應,以及觀察其在 HPV16小鼠治療模型中的抑瘤效果,比較分析聯閤免疫對小鼠免疫反應及治療腫瘤效果的影響.結果:異性聯閤免疫組均可檢測到較高水平的體液免疫,該2組針對 E6、E7特異性的 T 細胞免疫反應與同性聯閤免疫2組相比明顯提高,併在小鼠腫瘤治療模型中能抑製腫瘤生長.結論:異性聯閤免疫策略可明顯提高 HPV16 L2E7E6及 rAd5E7E6疫苗的 T 細胞免疫反應,且有效治療 HPV16相關腫瘤,為 HPV16 L2E7E6及 rAd5E7E6疫苗的應用提供瞭實驗基礎.
목적:탐색연합면역책략대인유두류병독16형(HPV16)치료역묘 L2E7E6화 rAdE7E6적면역효과적영향.방법:용 L2E7E6융합단백화중조선병독 rAd5E7E6이불동적연합면역정서분별면역 C57BL/6소서,통과검측기유발적체액면역화세포면역반응,이급관찰기재 HPV16소서치료모형중적억류효과,비교분석연합면역대소서면역반응급치료종류효과적영향.결과:이성연합면역조균가검측도교고수평적체액면역,해2조침대 E6、E7특이성적 T 세포면역반응여동성연합면역2조상비명현제고,병재소서종류치료모형중능억제종류생장.결론:이성연합면역책략가명현제고 HPV16 L2E7E6급 rAd5E7E6역묘적 T 세포면역반응,차유효치료 HPV16상관종류,위 HPV16 L2E7E6급 rAd5E7E6역묘적응용제공료실험기출.
Objective: To study the effectiveness of homologous and heterologous prime-boost strategies with hu?man papillomavirus(HPV) 16 L2E7E6 fusion protein and rAd5E7E6 in treating HPV associated tumors. Methods:We observed the prime-boost strategy efficacy of preventing outgrowth of HPV16-positive tumour cells in the mouse with a minimal residual disease setting, using HPV16 L2E7E6 fusion protein vaccine and a recombinant rAd5E7E6 vaccine expressing HPV16 E6 and E7 proteins. The cell-mediated immunity induced by different kind of prime-boost strategies was assessed by HPV16 E7 and E6 specific IFN-γ enzyme-linked immunospot (ELISPOT). The humoral immune response was messured by ELISA. Results: Heterologous prime-boost regimens could induce strong antibody response, and enhanced E7 and E6 peptide-specific IFN-γ secreting effector T cell responses compared to homologous vaccine regimens. These immune responses could partly prevent the TC-1 tu?mor cell bearing mince from developing into tumor. Conclusion: These data suggested that heterologous prime-boost regimens of HPV16 L2E7E6 and rAd5E7E6 vaccines could elicit stronger HPV16 E7 and E6 specific T cell response than the homologous prime-boost regimens, and were effective in therapeutic animal model. It provid?ed scientific basis for the further use of HPV16 L2E7E6 and rAd5E7E6 vaccines.
